A better understanding of glucagon kinetics and its dysregulation in humans with diabetes that results in abnormalities in circulating plasma glucagon concentrations should lead to rational and informed therapeutic strategies to mitigate both hyperglycemia and hypoglycemia in these individuals. The gene discussed is GCG; the disease is Hypoglycemia.